ICLR ICON PLC

$175.83

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About ICON PLC

ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and internationally. The company is headquartered in Dublin, Ireland.

Website: https://www.iconplc.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1060955
Address
SOUTH COUNTY BUSINESS PARK, LEOPARDSTOWN, DUBLIN 18, IE
Valuation
Market Cap
$11.26B
P/E Ratio
14.62
PEG Ratio
0.63
Price to Book
1.18
Performance
EPS
$9.53
Dividend Yield
Profit Margin
9.56%
ROE
8.44%
Technicals
50D MA
$177.50
200D MA
$242.02
52W High
$347.72
52W Low
$137.87
Fundamentals
Shares Outstanding
81M
Target Price
$213.62
Beta
1.24

ICLR EPS Estimates vs Actual

Estimated
Actual

ICLR News & Sentiment

Aug 22, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
SAN DIEGO, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Gyre Therapeutics ( "Gyre" ) ( Nasdaq: GYRE ) , an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, ...
Aug 22, 2025 • Benzinga SOMEWHAT-BULLISH
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - Gyre Therapeutics ( NASDAQ:GYRE )
SAN DIEGO, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Gyre Therapeutics ( "Gyre" ) GYRE, an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its ...
Jul 27, 2025 • Benzinga BULLISH
Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week ( July 21-July 25 ) : Are The Others In Your Portfolio? - Astera Labs ( NASDAQ:ALAB ) , Baker Hughes ( NASDAQ:BKR )
Medpace surged over 137% after crushing Q2 earnings estimates. Strong earnings and raised guidance drove sharp gains in pharma and tech names. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. These ten large-cap stocks were top performers last week.
Jul 24, 2025 • Benzinga SOMEWHAT-BULLISH
WHy ICON Stock Up After Q2 - Icon ( NASDAQ:ICLR )
Gross business wins rose 11% QoQ; net bookings beat target by 8% with a 1.02x book-to-bill ratio. FY25 EPS outlook narrows to $13-$14; share buyback program expanded to $1 billion. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Jul 24, 2025 • Benzinga SOMEWHAT-BULLISH
This Spotify Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Crown Castle ( NYSE:CCI ) , General Dynamics ( NYSE:GD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Joseph Gallo upgraded Varonis Systems, Inc.
Jul 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Icon PLC ( ICLR ) Q2 Earnings and Revenues Top Estimates
Icon PLC (ICLR) delivered earnings and revenue surprises of +2.52% and +1.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.111
50 articles with scored sentiment

Overall Sentiment:

Neutral

ICLR Reported Earnings

Apr 22, 2025
Mar 31, 2025 (Pre market)
-0.21 Surprise
  • Reported EPS: $3.19
  • Estimate: $3.40
  • Whisper:
  • Surprise %: -6.2%
Feb 19, 2025
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $3.43
  • Estimate: $3.43
  • Whisper:
  • Surprise %: 0.1%
Oct 23, 2024
Sep 30, 2024 (Post market)
-0.49 Surprise
  • Reported EPS: $3.35
  • Estimate: $3.84
  • Whisper:
  • Surprise %: -12.8%
Jul 24, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $3.75
  • Estimate: $3.68
  • Whisper:
  • Surprise %: 1.9%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.06 Surprise
  • Reported EPS: $3.47
  • Estimate: $3.41
  • Whisper:
  • Surprise %: 1.8%
Mar 12, 2024
Dec 31, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $3.46
  • Estimate: $3.44
  • Whisper:
  • Surprise %: 0.6%
Oct 25, 2023
Sep 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $3.30
  • Estimate: $3.28
  • Whisper:
  • Surprise %: 0.6%
Jul 26, 2023
Jun 30, 2023 (Post market)
0.03 Surprise
  • Reported EPS: $3.11
  • Estimate: $3.08
  • Whisper:
  • Surprise %: 1.0%
Apr 26, 2023
Mar 31, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $2.90
  • Estimate: $2.88
  • Whisper:
  • Surprise %: 0.7%

Financials